EWA
BDTX icon

EverSource Wealth Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

EverSource Wealth Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-183
Closed -$454 – 4333
2025
Q2 		$454 Buy
183
+117
+177% +$225 ﹤0.01% 3918
2025
Q1 		$102 Buy
+66
New +$138 ﹤0.01% 3827

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EverSource Wealth Advisors's BDTX Position: Q3 2025 in Review

EverSource Wealth Advisors sold out of Black Diamond Therapeutics (BDTX) in Q3 2025, closing a stake of 183 shares — an estimated $454 sold.

EverSource Wealth Advisors first reported a position in BDTX in Q1 2025 and held it in 2 quarters. The position peaked at $454 in Q2 2025. 91 funds tracked by Wall St. Rank hold BDTX as of Q3 2025.

  • EverSource Wealth Advisors reported no remaining Black Diamond Therapeutics position as of Q3 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 183 Black Diamond Therapeutics shares in Q3 2025, an estimated $454.
  • EverSource Wealth Advisors first reported a position in Black Diamond Therapeutics in Q1 2025 and held it in 2 quarters.
  • EverSource Wealth Advisors's Black Diamond Therapeutics position peaked at $454 in Q2 2025.
  • 91 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2025.

Based on EverSource Wealth Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.